Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055549 | 0.90 | TP53 (0.55) | KDM4ETP53MAPK1BRD4BRD2 | |
| SCHEMBL7122297 | 0.81 | KDM4E (0.48) | KDM4ETP53MAPK1BRD4BRD2 | |
| SCHEMBL7121742 | 0.81 | KDM4E (0.48) | KDM4ETP53MAPK1BRD4BRD2 | |
| SCHEMBL7121748 | 0.81 | KDM4E (0.48) | KDM4ETP53MAPK1BRD4BRD2 | |
| SCHEMBL7055158 | 0.78 | HTT (0.47) | CNR2RAB9ASMN1; SMN2POLBNPC1 | |
| SCHEMBL7291994 | 0.78 | TSHR (0.47) | KDM4ECNR2RAB9ASMN1; SMN2GFER | |
| SCHEMBL7053446 | 0.78 | TSHR (0.43) | CNR2RAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL8138126 | 0.77 | TSHR (0.46) | KDM4ECNR2RAB9ASMN1; SMN2GFER | |
| SCHEMBL8129987 | 0.77 | CNR2 (0.50) | KDM4ECNR2SMN1; SMN2MEN1TSHR | |
| SCHEMBL8130570 | 0.76 | TSHR (0.62) | RAB9ASMN1; SMN2NPC1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322622-B1 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | SPROUT PHARMACEUTICALS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1322622-B1 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | SPROUT PHARMACEUTICALS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1322622-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6521623-B1 | 1-(2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl)-3-(2-hydroxyethyl) -1,3-dihydro-2H-benzimidazol-2-one for example; treating anxiety disorders and psychological disorders, brain injuries | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | Salix Pharmaceuticals, Ltd | 2003-02-06 | — | — | US | disclosed |
| WO-2002024661-A2 | NEW N, N'-DISUBSTITUTED BENZIMIDAZOLONE DERIVATIVES WITH AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027823-A1 | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR3C | KDM4E 4451/4885TP53 4758/4885MAPK1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.